Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 31,346	$ 10,799
Accounts receivable, net of allowance for doubtful accounts of $25 and $0, respectively	62	27
Inventory, net	477
Prepaid expenses and other current assets	1,271	1,175
Other current assets of discontinued operations		498
Total current assets	33,156	12,499
Property and equipment, net of accumulated depreciation of $434 and $166 respectively	1,658	1,434
Intangible assets and other assets, net	5,789	6,341
Total assets	40,603	20,274
Current liabilities:
Current debt		6,731
Accounts payable	921	1,887
Accrued expenses	494	918
Deferred revenue	139	56
Current liabilities of discontinued operations		20
Total current liabilities	1,554	9,612
Deferred tax liability		2,500
Warrant liability	374	13,087
Derivative liability		534
Other long-term liabilities	344	142
Total liabilities	2,272	25,875
Commitments
Shareholders' equity (deficit):
Common stock, $0.001 par value; 1,100,000,000 shares authorized; 655,747,608 and 95,678,255 issued and outstanding, respectively	656	96
Common stock-subscription receivable	(2,004)	(550)
Additional paid-in capital	111,754	43,734
Accumulated deficit	(72,075)	(49,349)
Total Fibrocell Science, Inc. shareholders' equity (deficit)	38,331	(6,069)
Noncontrolling interest		468
Total equity (deficit) and noncontrolling interest	38,331	(5,601)
Total liabilities, preferred stock, shareholders' equity (deficit) and noncontrolling interest	40,603	20,274
Series A Preferred Stock
Current liabilities:
Preferred stock
Series B Preferred Stock
Current liabilities:
Preferred stock
Series D Preferred Stock
Current liabilities:
Preferred stock
Series E Preferred Stock
Current liabilities:
Preferred stock